449 related articles for article (PubMed ID: 18358560)
21. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer.
Kim DH; Nelson HH; Wiencke JK; Christiani DC; Wain JC; Mark EJ; Kelsey KT
Oncogene; 2001 Mar; 20(14):1765-70. PubMed ID: 11313923
[TBL] [Abstract][Full Text] [Related]
22. Lack of association between CpG island methylator phenotype in human gastric cancers and methylation in their background non-cancerous gastric mucosae.
Enomoto S; Maekita T; Tsukamoto T; Nakajima T; Nakazawa K; Tatematsu M; Ichinose M; Ushijima T
Cancer Sci; 2007 Dec; 98(12):1853-61. PubMed ID: 17900260
[TBL] [Abstract][Full Text] [Related]
23. Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling.
Suzuki M; Wada H; Yoshino M; Tian L; Shigematsu H; Suzuki H; Alaa M; Tamura H; Fujiwara T; Nagato K; Motohashi S; Moriya Y; Hoshino H; Yoshida S; Shibuya K; Hiroshima K; Nakatani Y; Yoshino I
Ann Surg Oncol; 2010 Mar; 17(3):878-88. PubMed ID: 19841986
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
[TBL] [Abstract][Full Text] [Related]
25. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus.
Kusano M; Toyota M; Suzuki H; Akino K; Aoki F; Fujita M; Hosokawa M; Shinomura Y; Imai K; Tokino T
Cancer; 2006 Apr; 106(7):1467-79. PubMed ID: 16518809
[TBL] [Abstract][Full Text] [Related]
26. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
[TBL] [Abstract][Full Text] [Related]
27. Status and significance of CpG island methylator phenotype in endometrial cancer.
Zhang QY; Yi DQ; Zhou L; Zhang DH; Zhou TM
Gynecol Obstet Invest; 2011; 72(3):183-91. PubMed ID: 21968189
[TBL] [Abstract][Full Text] [Related]
28. Promoter methylation primarily occurs in tumor cells of patients with non-small cell lung cancer.
De Jong WK; Verpooten GF; Kramer H; Louwagie J; Groen HJ
Anticancer Res; 2009 Jan; 29(1):363-9. PubMed ID: 19331174
[TBL] [Abstract][Full Text] [Related]
29. Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Williams NN; Kaiser LR; Croce CM
Cancer Res; 2003 Jun; 63(12):3352-5. PubMed ID: 12810670
[TBL] [Abstract][Full Text] [Related]
30. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer.
Kikuchi S; Yamada D; Fukami T; Masuda M; Sakurai-Yageta M; Williams YN; Maruyama T; Asamura H; Matsuno Y; Onizuka M; Murakami Y
Clin Cancer Res; 2005 Apr; 11(8):2954-61. PubMed ID: 15837747
[TBL] [Abstract][Full Text] [Related]
31. Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior.
Geli J; Kiss N; Karimi M; Lee JJ; Bäckdahl M; Ekström TJ; Larsson C
Clin Cancer Res; 2008 May; 14(9):2551-9. PubMed ID: 18451216
[TBL] [Abstract][Full Text] [Related]
32. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
33. High CpG island methylator phenotype is associated with lymph node metastasis and prognosis in gastric cancer.
Chen HY; Zhu BH; Zhang CH; Yang DJ; Peng JJ; Chen JH; Liu FK; He YL
Cancer Sci; 2012 Jan; 103(1):73-9. PubMed ID: 22017425
[TBL] [Abstract][Full Text] [Related]
34. Critical role of deltaDNMT3B4/2 in regulating RASSF1A promoter-specific DNA methylation in non-small cell lung cancer.
Wang SH; Liu NH; Wang J; Bai H; Mao L
Chin Med J (Engl); 2008 Sep; 121(17):1712-21. PubMed ID: 19024105
[TBL] [Abstract][Full Text] [Related]
35. Molecular genetics of small cell lung carcinoma.
Wistuba II; Gazdar AF; Minna JD
Semin Oncol; 2001 Apr; 28(2 Suppl 4):3-13. PubMed ID: 11479891
[TBL] [Abstract][Full Text] [Related]
36. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
[TBL] [Abstract][Full Text] [Related]
37. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer.
Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J
Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968
[TBL] [Abstract][Full Text] [Related]
38. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
[TBL] [Abstract][Full Text] [Related]
39. Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in non-small cell lung cancer.
Xinarianos G; McRonald FE; Risk JM; Bowers NL; Nikolaidis G; Field JK; Liloglou T
Hum Mol Genet; 2006 Jul; 15(13):2038-44. PubMed ID: 16698880
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.
Tomizawa Y; Iijima H; Nomoto T; Iwasaki Y; Otani Y; Tsuchiya S; Saito R; Dobashi K; Nakajima T; Mori M
Lung Cancer; 2004 Dec; 46(3):305-12. PubMed ID: 15541815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
